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Background: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with
conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish
dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro.
Methods: Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA
mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39
dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive
dilated cardiomyopathy patients, referred for a family evaluation and mutation screening.
Results: We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and
p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized
by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia,
although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation,
fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of
cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation
was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model.
Conclusions: In conclusion, in the two referral centre populations, the screening revealed five mutations among 66
heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44
consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients
with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members.
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Lamin A/C (encoded by LMNA on 1q21) is a type V
intermediate filament protein important for structural
integrity and appropriate function of the nucleus [1]. Over
350 mutations were reported (for the list of mutations, see
UMD-LMNA database at www.umd.be/LMNA/) and they
are associated with numerous disorders including dilated* Correspondence: rploski@wp.pl
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overlapping phenotype [2].
DCM is a major cause of heart failure (HF) with a
familial predisposition found in 20 to 50% of cases.
Mutations in LMNA are among the most frequently
detected mutations in DCM [3,4], especially in cases
with conduction system disease [5]. DCM patients with
LMNA mutations have poor prognosis with life-threatening
ventricular arrhythmias, progression to heart failure and
high risk of sudden cardiac death (SCD) [6,7]. In 2005, a
Canadian-Irish-Polish joint study demonstrated LMNA
mutations in 4.4% of consecutive DCM cases [8]. In
order to extend these observations, we embarked on
another study to identify LMNA mutations, estimate their
frequency among DCM patients and characterize their
effect. The study comprised of two patient populations:
heart transplant (HTx) recipients or patients referred for
HTx evaluation and consecutive DCM patients referred
for familial evaluation and mutation screening.
Methods
Patients
Between January, 2008 and June, 2012 two cohorts of
patients in the Institute of Cardiology, Warsaw were
studied. The first cohort consisted of 66 DCM patients
(61 men, mean age 42.2 ± 14 years) from the Outpatient
Heart Failure Clinic (Warsaw, Poland) including 27 HTx
recipients and 39 patients with DCM-related advanced
HF referred for HTx (mean LVEF 23.5 ± 9.8%). Data
concerning the HTx recipients were reviewed to confirm
the diagnosis of DCM prior to HTx. The second cohort
included 44 consecutive DCM patients (34 men, mean
age 42. 4 ± 12.4 years, mean LVEF 30.3 ± 9.5) referred
for a family evaluation to the Unit for Screening Studies
in Inherited Cardiovascular Diseases. DCM was diagnosed
according to the ESC criteria [9] with left ventricular
ejection fraction below 45% and left ventricular end-
diastolic diameter exceeding 117 percent of predicted value
according to age and body surface area, confirmed over
six-month period. In all probands, coronary angiography
was performed. One patient had an endomyocardial
biopsy performed based on clinical indications. DCM
was considered familial when two members met the criteria
for diagnosis of DCM in probands. CPK level was obtained
whenever possible. Once a mutation was identified adult
first-degree relatives of the mutation carriers were offered
mutation screening. Individuals with a previously published
[8,10,11] pathogenic LMNA mutations (p.Tyr481*,
c.1443C > G; p.Arg541Cys, c.1621C > T; p.Arg541Gly,
c.1621C > G) were included, when new follow-up
data were available.
Population screening to exclude the presence of
p.Ser431* (c.1292C > G), p.Val256Gly (c.767 T > G)
and p.Gly400Argfs*11 (c.1197_1240del44) amonghealthy individuals was performed in 215 adult Caucasian
subjects with no history of cardiovascular diseases as
judged by an interview, randomly selected from a
previously studied population cohort [12].
The study was conducted in accordance with the
principles outlined in the 1964 Declaration of Helsinki
and its later amendments as well as the current ethical
laws of Poland and Canada. Prior to enrollment in the
study written informed consent was obtained from
every participant. This consent as well as the whole
project obtained approval from the Institute of Cardiology
Ethics Committee.
Mutation screening
DNA was extracted from the peripheral blood by phenol
extraction. The twelve exons of the LMNA gene along with
flanking intronic regions were amplified by polymerase
chain reaction using primer pairs described in earlier
studies (list available at www.dmd.nl/LMNA_primers.
html) or designed with the Primer3 program [13] (v. 0.4.0,
sequences available upon request). The amplified regions
were screened by direct sequencing with ABI BigDye
Terminator sequencing kit using ABI 3130 Genetic
Analyzer (Applied Biosystems, Foster City, USA). The
results were analyzed with Variant Reporter 1.1 Software
(Applied Biosystems).
Newly identified mutations were confirmed by a
non-sequencing method. p.Ser431* and p.Val256Gly were
confirmed with Wave DHPLC instrument (Transgenomic,
Omaha, USA), while p.Gly400Argfs*11, being a deletion
of 44 nucleotides, was visualized by 2% agarose gel
electrophoresis and ethidium bromide staining. The
presence of the said mutations was excluded among
healthy individuals either by direct sequencing (p.Ser431*),
gel electrophoresis of PCR amplicon (p.Gly400Argfs*11) or
by PCR-RFLP (p.Val256Gly), in which case a Fermentas
(Vilnus, Lithuania) enzyme selected by PIRA-PCR software
[14] was used. In presence of the mutation, the digestion of
the PCR product yielded two bands of 101 bp and 17 bp,
which were visualized by 3% agarose gel electrophoresis
and ethidium bromide staining. Aminoacid and nucleotide
are numbered according to NM_170707.3 (http://www.
ncbi.nlm.nih.gov/nuccore/NM_170707).
Expression analysis
To characterize the consequences of the LMNA mutation
at the cellular level, transient cell transfections were
performed in C2C12 mouse myoblast cells with wild type
or mutated lamin A (NM_170707.3) and lamin C
(NM_005572.3) mRNA expressed as fusions to the
C-terminus of cyan fluorescent protein (pECFP-C1)
and yellow fluorescent protein (pEYFP-N1), respectively
(Clonetech Laboratories). Mutations were introduced via
site-directed mutagenesis (Stratagene or QuikChange II
Saj et al. BMC Medical Genetics 2013, 14:55 Page 3 of 10




TCATGCTGGGCCCGC-3′. All the inserts were system-
atically verified by sequencing. C2C12 mouse myoblasts
cells (ATCC) were cultured in Dulbecco’s Modified Eagle
Medium (Invitrogen) supplemented with 10% FBS and
1:100 L-glutamine, and incubated at 37°C with 5% CO2.
The transfection was performed by incubating 0.5 μg of
fusion protein construct and Metafectene®Pro fol-
lowing the manufacturer protocol (http://www.biontex.
com/con_4_6_4/cms/upload/pdf/Manual_METAFECTENE-
PRO_en.pdf). Cells were grown for 18–21 hours. C2C12
images were captured on a Carl Zeiss axioimager M2
research microscope using the Axiovision AxioVs40 V
4.8.1 acquisition software.
Endomyocardial biopsy
Right ventricular endomyocardial biopsy was obtained by
transvenous femoral approach using the Cordis bioptome.
Biopsy material was examined by light and electron
microscopy. Under light microscopy, non-specific findings
were identified.
Evolutionary conservation
Evolutionary conservation of mutated amino acids was
examined using Ensembl (release 64) database. The
sequences of cow, rat, hyrax, sloth, chicken, Anolis
lizard, Xenopus frog and zebrafish were obtained
using BLASTP search tool and then juxtaposed with
a short fragment of lamin A/C protein sequence
encompassing the mutated residue. ClustalW2 was
used for sequence alignment [15].
Results
Among the 66 patients from the first cohort (Heart
Failure Clinic) five harbored LMNA mutations (p.Ser431*,
p.Thr510Tyrfs*42, p.Arg89Leu, p.Tyr481*, p.Arg541Cys).
Among the 44 subjects from the second cohort (Unit
for Screening Studies in Inherited Cardiovascular Disease)
four mutations were found (p.Val256Gly, p.Gly400Argfs*11,
p.Gln246* and p.Arg541Gly) (Figure 1). The prevalence of
LMNA mutations in the total cohort (N = 110) was 8%. To
the best of our knowledge, three of the observed mutations
(p.Ser431*, p.Val256Gly and p.Gly400Argfs*11) are novel.
Four of the nine mutations were identified in the setting of
familial disease (families B, C, F, G in Figure 2), four in fam-
ilies with positive family history of HF (families A, D, E, H)
and one in a patient with a sporadic DCM (p.Val256Gly)
(family I). General characterization of the studied group is
given in Table 1 and genotype-phenotype correlations in
the families with lamin A/C mutations in the Table 2.Clinical evaluation of mutation carriers
More than two thirds of the LMNA mutation carriers
were male (n = 17, 68%). The most frequent abnormality
was conduction disease in 18 (72%) of mutation carriers,
followed by complex ventricular arrhythmia (60%) and
atrial fibrillation (36%). The relatively low prevalence of
heart failure in the study (36%) can be explained by the
fact that at the time of the study 6 patients already had
heart transplantation (24%). In 8 of 23 subjects with
measured CPK (34.8%), elevated CPK level > 308U/l was
found, indicating subclinical skeletal muscle involvement.
Five mutation carriers were asymptomatic.The novel
p.Gly400Argfs*11 (c.1197_1240del44) mutation was
identified in the proband as well as in two family E
members (the proband’s sister and son). In the proband
and his sister, the onset of the disease along with sinus and
AV node dysfunction only occurred at the age of 50 and 51,
respectively. This was followed by atrial fibrillation/flutter
in both patients and reduced left ventricular ejection
fraction in the proband only.
The carriers of the novel p.Ser431* mutation, the
proband and his brother, had the onset of symptoms
at the age of 37 and 34, respectively, and HTx at the
age of 43 and 50, respectively. This family (F) history
was previously reported by us [15] as a DCM family
with conduction disease.
The third novel mutation, p.Val256Gly was identified
in the 26-year-old patient (family I) with four-year
history of ventricular arrhythmia and AV node conduction
disease. The patient received an ICD, his LVEF was
gradually decreasing with persistent troponin I leakage.
At the age of 27, the patient developed persistent atrial
flutter/fibrillation. Unfortunately, none of the proband’s
family members were available for either clinical or
genetic examination.In the three families (C, D, and G) with
already published mutations (Table 2), the phenotype was
typical of cardiolaminopathy with conduction defects. In
two probands, supraventricular/ventricular arrhythmia
followed by heart failure led to heart transplantation at 34
years of age (family C, p. Arg89Leu) and at 45 years
of age (family G, p.Thr510Tyrfs*42, c.1526_1527insC,
electrocardiogram of the carrier IV-1 shown in Figure 3).
The proband from family D (Gln246Stop) suffers
from progressive heart failure.p.Arg541Cys (family A)
and p.Arg541Gly (family B) mutations were previously
reported by us [9,10]. They are both associated with
regional wall motion abnormalities within the left
ventricle. Post-publication follow-up revealed that the
disease in the p.Arg541Cys carrier progressed leading
to HTx at the age of 22. Similarly to the p.Val256Gly
carrier, the proband with the p.Arg541Gly mutation
currently presents an LVEF of 35%, is on 50 mg/day
carvedilol and has persistent troponin I leakage, indicating
an aggressive form of the disease. For the family H with
Figure 1 Chromatograms of mutations identified in the study. A - p.Arg541Cys (c.1621C > T), B - p.Arg541Gly (c.1621C > G), C - p.Arg89Leu
(c.266G > T), D - p.Gln246* (c.736C > T), E - p.Gly400Argfs*11 (c.1197_1240del44), F - p.Ser431* (c.1292C > G), G - p.Thr510Tyrfs*42
(1526_1527insC), H - p.Tyr481* (c.1443C > G), I - p.Val256Gly (c.767 T > G).
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follow-up data. Three of four of the proband’s children
were already symptomatic LMNA mutation carriers in
their second decade. An ICD was implanted in the
19-year-old mutation carrier due to nsVT on Holter
monitoring but so far (for 5 years) has not discharged
adequately. DDD pacemaker was implanted in the
14-year-old girl. Recently, she developed nsVT that
was treated with 50 mgmetoprolol tartrate daily.
Serum CPK levels in both girls remain mildly elevated at
478 and 656 U/l, respectively, indicating subclinical
muscle involvement. Their younger brother received
metoprolol for seven years due to nsVT.Ultrastructural study of p.Thr510Tyrfs*42 mutation
patient’s cardiomyocytes
Ultrastructural study of the cardiomyocytes showed
important alteration in nuclear distribution and
organization (Figure 4) with extensive nuclear deformations
in all cardiomyocytes. Nuclei in control cardiomyocytes
from a DCM patient without LMNA mutation were mostly
regular in size and shape and appeared generally round or
ovoid with a smooth nuclear outline (not shown). Affected
nuclei were highly elongated, irregular and misshapen
(Figure 4A, B), some had a cauliflower appearance, which
was not observed in normal cardiomyocytes. Remodelingof heterochromatin distribution was manifested by focal
breakage or leakage of chromatin forming an area of
various size (Figure 4C), which may indicate a change
in the organization and anchoring of chromatin to
the nuclear lamina.Expression of the p.Val256Gly mutation in C2C12 cell line
Lamin A and lamin C constructs were co-transfected in
C2C12 cells. As shown on Figure 5A, cells transfected
with wild type constructs displayed regular lamin A/C
nuclear veil. After transfection of the p.Val256Gly mutated
lamin A and lamin C constructs, we observed aggregates
where both lamins cosegregate (Figure 5B). Since lamin A
and C may have different roles [16-18], we evaluated the
effect of the p.Val256Gly mutation separately for the lamin
A and lamin C. As previously observed [16], transfection
of wild type lamin C alone leads to a granulated aspect of
the nucleus (Figure 5E), while transfection of wild type
lamin A alone results in a veil aspect (Figure 5C). In the
case of the p.Val256Gly mutation, when mutated lamin C
constructs were transfected into C2C12 cells, large
aggregates were observed (Figure 5F). These aggregates
were much smaller in cells transfected with p.Val256Gly
lamin A construct (Figure 5D). This suggests that the
observed phenotype results from abnormal distribution of
p.Val256Gly lamin A and C independently.
Figure 2 Pedigrees of the families with LMNA mutations
identified in this study. Roman numerals indicate generations. The
squares mark males, while the circles mark females. Diagonal line
across the symbol indicates that the individual is deceased. Grey-
filled symbols denote that the probable cause of death was related
to cardiac disease, black-filled symbols denote the diagnosis of DCM,
while half-filled symbols denote a conduction disease and/or
arrhythmia with normal LV function. Quarter-filled symbols describe
subjects with minor or other cardiac abnormalities. Black arrow
describes the proband. “+” and “-” indicate the presence of a
mutation or lack thereof, respectively. A - Arg541Cys,
B - Arg541Gly, C - Arg89Leu, D - Gln246*, E - Gly400Argfs*11, F -
Ser431*, G - Thr510Tyrfs*42, H - Tyr481*, I - Val256Gly.
Table 1 Overall characteristics of mutation carriers
Variable Clinical data
Number of mutation carriers (%) 25
Type of mutation 6-missense/19-nonsense
Male sex (%) 17 (68)
Number of asymptomatic carriers;
mean age ± SD
5; 28,2 ± 7,1 years
Mean age at the onset of symptoms ± SD 29,9 ± 13,3 years
Conduction disease/AV block I, II 18/25 (72%)/ 13/25 (52%)
Atrial fibrillation (%) 9/25 (36%)
Complex ventricular arrhythmia (VT/VF) 15/25 (60%)
Heart failure, n (%), mean age ± SD 9/25 (36%), 36.9 ± 11.3 years
Pacemaker implantations (%) 8 (32%)
Cardioverter-defibrillator implantations (%) 14 (56%)
Adequate ICD discharges, n (%);
time to first intervention
4 (28.6%); 1.8-20 months
Subjects with CPK measured; elevated
CPK > 308U/l (%)
23; 8 (34.8%)
Heart transplantation (%), mean age ± SD 6/25 (24%), 39,2 ± 9.9 years
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Among the 66 HTx recipients or patients referred for
HTx evaluation (Heart Failure Clinic) and the 44
consecutive DCM patients referred for familialevaluation to the Unit for Screening Studies in
Inherited Cardiovascular Disease, we identified nine
LMNA mutations including p.Arg541Cys, p.
Arg541Gly and p.Tyr481* previously described by
our team and three novel mutations: p.
Gly400Argfs*11, p.Ser431* and p.Val256Gly.
Two of the novel mutations, p.Gly400Argfs*11 and
p.Ser431*, are predicted to result in truncated lamins
lacking, respectively, 254 and 233 amino acids from
the lamin A protein and thus are likely to be patho-
genic. It should be mentioned that pathogenicity was
observed for nonsense mutations occurring even
closer to the C terminus of lamin protein: p.Gln432*
[19] and p.Tyr481* [8].
The pathogenicity of p.Val256Gly, the third novel
mutation in our study, is supported by the fact that
transient transfection of the mutated cDNA in C2C12
cells leads to abnormal lamin aggregates in the nucleus,
by the absence of occurrence of the mutation among 215
controls and by evolutionary conservation of the mutated
residue (Figure 6). Mutated lamin A and C aggregate
formation is mutation-specific and has been observed
both in vivo and in cellular models. Skin fibroblasts
isolated from patients with cardiac- or skeletal-specific
laminopathies most often had abnormal nuclear shape
[20] with abnormal lamin A and C distribution. Lamin A
and C were found in the form of aggregates close to the
lamina which did not interact with emerin, DNA or RNA
[21], in a honeycomb pattern [20] or distributed unevenly
along the inner nuclear lamina [22]. Several LMNA
mutations are known to result in the aggregation of
lamins in vitro [8,11,23-28]. However, phenotype-genotype
Table 2 Families with lamin A/C gene mutations: genotype-phenotype correlations
















p.Arg541Cys (c.1621C > T) 10/ Tail, end of Lamin
Tail Domain (LTD)




1 1 (100%) 1 (100%) 1 at 15 y Yes, at 22 y
Family A
p.Arg541Gly (c.1621C > G) 10/ Tail, end of Lamin
Tail Domain (LTD)
No DCM + CD (NBBB)
and SWMA
Familial 3 2 (66%) 2 (66%) 0 No
Family B
p.Arg89Leu (c.266G > T) Rod domain, (MLIP
interaction region, Coil 1B)
No DCM + AVB Familial 1 1(100%) 1(100%) 0 Yes, at 34 y
Family C




Tail Yes DCM + AVB + SSS Positive family 3 2 (66%) 0 2 (66%) 0 0





No DCM + AVB Familial 5 4 (80%) 4 (80%) 3(60%) 1 F at 25 y Yes, proband
at 45 y
Family G and 1 M at 56 y
p.Gln246* (c.736C > T) Rod domain, Coil 2 No DCM + AVB Positive family 2 1 (50%) 1 (50%) 0 No
Family D history of HF
p.Ser431* (c.1292C > G) Tail Yes DCM + AVB Familial 5 4 (80%) 3 (60%) Proband at 43 y, Yes, proband
at 43 y,
Family F Another M
at 50 y
p.Tyr481* (c.1443C > G) Tail, Lamin Tail
Domain (LTD)
No DCM + AVB Positive family
history of HF
4 4 (100%) 4 (100%) 2(50%) 0 Yes, proband
at 40 y
Family H
Total number N = 25 N = 20 N = 17 N = 8 N = 4 N = 6
DCM, dilated cardiomyopathy; AVB, atrioventricular block; HF, heart failure; y-years, SWMA, segmental wall motion abnormalities; SSS, sick sinus syndrome; LBBB, left bundle branch block; NBBB, nonspecific bundle


















Figure 3 ECG of 26-year-old patient with Thr510Tyrfs*42 mutation. Sinus rhythm 60/min with first degree AV block (PQ = 300 ms). Left axis
deviation, incomplete RBBB. Poor R wave progression in the leads V1-V4. Low voltage QRS in the limb leads.
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cellular phenotype cannot be predicted based on the
nonsense versus missense nature of the mutation. As
for now, determining the cellular phenotype requires
direct observation of cells expressing the mutated
lamins. We and others have shown increased mobility of
mutant lamins as well as a reduced ability to form contacts
with the inner nuclear membrane [16,26]. It has been
postulated that the mutated lamin aggregates reduce
the lamina stability leading to cellular dysfunction.Figure 4 Ultrastructural study by electron microscopy of endomyocar
Misshapen nuclei, with deep invaginations of nuclear membrane. A - abno
nuclear membrane (arrow), C - halving of the nucleus (arrow) (original magOf the nine identified mutations, three (Arg89L,
Gln246Stop and Val256Gly) were located in the central
rod domain, the remaining six in the tail domain of the
protein. The type of cardiomyopathy and the course of
the disease was similar regardless of the site of the muta-
tion except for mutations occurring at the Arg541 pos-
ition that were associated with segmental wall motion
abnormalities in both probands (Arg541Gly and
Arg541Cys carriers). Similarly, there was no significant
difference regarding phenotype and course of the diseasedial biopsy of the patient with the Thr510Tyrfs*42 mutation.
rmal distribution of chromatin (arrow), B - focal breakage of the
nification × 15000).
Figure 5 C2C12 cells transiently transfected with mutant lamin A and lamin C in CFP and YFP fluorescent expression vectors,
respectively: A - Cotransfection of wild type lamin A and wild type lamin C, B - cotransfection of p.Val256Gly-mutated lamin A and
p.Val256Gly-mutated lamin C, C - transfection of wild type lamin A, D - transfection of p.Val256Gly-mutated lamin A, E - transfection of wild
type lamin C, F - transfection of p.Val256Gly-mutated lamin C. The level of magnification is 63X on Zeiss plan -Apochromat 63X/1.4 oil objective.
Saj et al. BMC Medical Genetics 2013, 14:55 Page 8 of 10
http://www.biomedcentral.com/1471-2350/14/55between missense and nonsense mutation carriers. None
of thefemale patient had severe heart failure, three of
them received an ICD, one a pacemaker for conduction
disease.
The presentation of the disease associated with the
p.Gly400Argfs*11 mutation, characterized by sinus
and AV node dysfunction, occurred late in the life of
the two patients, at the beginning of their sixth decade.
Sinus node dysfunction at the onset of the disease is not
frequently reported with LMNA mutation. Thus, this
mutation may be associated, at least in this family,
with late presentation and no phenotypic differences
between genders.
The two remaining novel mutations p.Ser431* and
p.Val256Gly were associated with typical phenotype
of DCM and conduction disease with ventricular
arrhythmias. The onset occurred in the late third/fourthFigure 6 The conservation of Val256 residues (bordered) across differ
chains, purple - basic residues, blue - acidic, green - residues with unchargand third decade, respectively. In the case of the p.Ser431*
mutation, we did not observe any gender related differ-
ences in the severity or the disease onset. The 29-year-old
carrier received an ICD due to complex ventricular
and supraventricular arrhythmia, and her aunt, who
became symptomatic at the age of 50, received an
ICD at the age of 52.
The p.Gln246* mutation was previously described [29].
It was associated with DCM and AVB in one patient
who remained asymptomatic until the age of 40. This is
similar to our findings. In the present study, the proband
developed DCM at 39 years of age with the first symptoms
occurring four years earlier. He is currently a NYHA
class III patient with a LVEF of 40%. Due to frequent
episodes of nsVT, the pacemaker was upgraded to an
ICD at the age of 40. Meanwhile, his mutation carrier
brother remains asymptomatic at 36 years of age andent species. If viewed in color: red - residues with hydrophobic side
ed polar side chains.
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p.Gln246* mutation is not associated with an increased
risk of sudden cardiac death or life-threatening arrhythmia
in the fourth decade and/or its penetrance may be
incomplete by that time.
The p.Arg89Leu mutation was identified by several
research teams [30-32] and, almost identically to our
findings, resulted in aggressive, quickly progressing HF
leading to HTx or SCD within just a few years of the
disease onset. The onset of symptoms occurred in the third
and fourth decade and patients experienced AV block, AF,
ventricular tachyarrythmias and were quickly classified to
III or IV NYHA functional class. The p.Arg89Leu mutation
is located in the central rod domain (Coil 1B), which is also
the location of the p.Val256Gly mutation, characterized by
a similarly aggressive phenotype.
The p.Thr510Tyrfs*42 was reported twice before. It
was associated with an idiopathic DCM phenotype in a
25-year-old NYHA class II patient with reduced LVEF
(25%), LV dilatation (LVEDD of 61 mm), first degree AVB
and no apparent clinical evidence of myopathic disease
except for an increased CPK level (600 U/l) [33]. This
report did not describe the severe arrhythmia which is a
typical phenotype among the p.Thr510Tyrfs*42 mutation
carriers in our study. Moreover, this insertion also
appeared in an EDMD male patient who was diagnosed at
the age of 51, but experienced prior cardiac abnormalities:
arrhythmia in his twenties, followed by a pacemaker
implantation and, finally, HTx at the age of 51 [34]. His
EDMD symptoms did not appear until he was 50
(mild proximal upper weakness) [34]. Therefore, it
seems that the Thr510Tyrfs*42 mutation may begin
with cardiac involvement and progress toward EDMD
phenotype later in life. In our study, three out of five
mutation carriers, the 55-, 24-, and 18-year-old males,
exhibited subclinical elevation of serum CPK level. The
pathological conditions induced by the p.Thr510Tyrfs*42
mutation were also visualized by electron microscopy of
endomyocardial biopsy. The mutation caused misshapen
nuclei and altered heterochromatin distribution in
cardiomyocytes. The latter seemed broken and leaking,
which may indicate abnormal organization and anchoring
of the chromatin to nuclear lamina (Figure 4).
Clinically, the male carriers of the p.Val256Gly and
p.Arg541Gly mutations, who have gradually decreasing
LVEF accompanied by troponin I leakage, suggestive of
relentless course leading to severe HF, are of particular
concern. Recently, selumetinib was found to preserve
cardiac function and improve survival in cardiomyop-
athy caused by mutation in the lamin A/C gene [35].
Selumetinib blocks extracellular signal-regulated kinase1/2
(ERK1/2) signaling pathway, which is activated in response
to HF and, specifically, DCM. In our opinion, LMNA
mutation carriers with troponin I leakage should beconsidered as first candidates for clinical trials to halt
the progression of the disease.
Conclusions
In conclusion, in the two referral centre populations, the
screening revealed five (7,6%) mutations among the 66
HTx recipients or patients referred for HTx evaluation
and four (9,1%) mutations within the 44 consecutive
DCM patients referred for familial evaluation. DCM
patients with LMNA mutations have poor prognosis,
however considerable clinical variability is present
among family members. This intrafamilial variability
in carriers with truncating LMNA mutations does not
seem to be gender dependent.
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